(866) 850-9555
help@netcancerawareness.org

NCAN News

Conquer Magazine’s 2016 Heroes of Hope Book

Conquer Magazine’s 2016 Heroes of Hope Book featuring Maryann Wahmann of NCAN & Cindy Lovelace of The Healing NET Foundation!
In 2016, Conquer Magazine released their Heroes of Hope: Celebrating the Patient Voice book. Featured are Heroes of Hope WINNER Maryann Wahmann, President of NCAN, and Heroes of Hope nominee Cindy Lovelace of The Healing NET Foundation.

Again, we would like to congratulate both Maryann and Cindy on their nominations for the 2016 Heroes of Hope Award, as well as a big congratulations to Maryann Wahmann on being the 2016 Heroes of Hope award recipient! The community thanks you both for all of the hard work and dedication you both give back to us!

For more information on NCAN, you can find that here at www.netcancerawareness.org!

For more information on The Healing NET Foundation, you can find that here at www.thehealingnet.org!

Please Follow & Like Us:
Read more

Five Reasons to Attend a Neuroendocrine Cancer Patient Conference!

Educational opportunities. No matter how experienced you are about handling your disease, everyone can learn. Being treated for a rare cancer can often be isolating, and without exposure to a variety of points of view, we can miss new ideas and trends that can impact our futures. The educational aspect of a conference can expose you to new treatment regimens and therapies and help you discover how to be a more productive advocate for your treatment and care.
Networking with peers. Patient conferences provide a great opportunity to network. Often patients and caregivers from different regions of the country can become valuable resources for referrals and best-practices. Avoiding your peers for whatever reason you have can actually limit you own success in fighting neuroendocrine cancer. You will find that the people who come together at a conference can help each other uncover ideas and spark inspiration when they get to know each other on a personal level.
Encounter the vendors & suppliers who provide the therapies you need. Too often people shy away from exhibitors at conferences. They fear they will have to talk to salespeople, but these industry suppliers are some of the best people for you to get to know if you want to learn more about the current direction of treatment. Discovering innovative products and services for your business is critical to your treatment and care in today’s fast-paced world. Invest time with the sponsors at the event and turn them into your friends and allies.
Position yourself as an expert. It has been suggested that well over half the requests by neuroendocrine cancer patients to their physicians for specific treatments are honored. A neuroendocrine cancer patient conference is the perfect opportunity to build your knowledge and become a better advocate for your health! You will hear directly from experts. Save your life by making sure you know enough to participate in your care so you are getting the best treatment plan possible.
Have fun. Being a neuroendocrine cancer patient or caregiver is hard work and it is stressful. All work and no play can get old fast. Patient conferences can add a layer of enjoyment to managing your disease by mixing a social aspect into your patient journey. Taking an extra day at the beginning or end of the trip to explore or visit friends in the region is also a great way to maximize the investment in travel. Never underestimate the power of a little fun mixed with some interesting people!
The internet won’t replace the conference experience. Many falsely believe that since they can now access industry information via the internet that the days of the live meeting are gone. The truth is, meetings are more important than ever. The value in meetings comes from the human-to-human connections that occur. Often people cite the serendipidous “hallway-conversations” that they have with other attendees as the most valuable parts of attending an event. While these are not on the agenda, or mentioned in the learning objectives, when two or more people begin to discuss topics on a deeper and personal level, the success of the event to those involved becomes irreplaceable. It is the people that bring the ROI to your time at a conference.
NCAN has upcoming conferences scheduled for 2018. Why not make it your business to attend at least one of them?

Please Follow & Like Us:
Read more

FDA Approves Lexicon Drug XERMELO!

FDA Approves Lexicon Drug Xermelo (TELOTRISTAT ETHYL) 250 MG as first and only oral treatment for Carcinoid Syndrome Diarrhea in cancer patients with Metastatic Neuroendocrine Tumors!
First-In-Class: Tryptophan Hydroxylase Inhibitor Orphan Drug XERMELO Now Available to Treat Rare and Debilitating Condition Characterized by Frequent, Severe Diarrhea
Conference Call and Webcast at 5:00 pm Eastern Time

The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELO (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapyi. Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors (mNETs)ii. XERMELO targets the overproduction of serotonin inside mNET cellsiii, providing a new treatment option for patients suffering from carcinoid syndrome diarrhea. This new treatment is now available by prescription and will be in select specialty pharmacies beginning March 6, 2017.
“Today’s approval of XERMELO represents a shift in the treatment paradigm of carcinoid syndrome diarrhea for cancer patients who are inadequately controlled by SSA therapy, and until now, have had limited options to manage this debilitating condition,” said Lonnel Coats, Lexicon’s president and chief executive officer. “We are proud to have discovered and developed this ground-breaking orphan drug, and it is an honor to make it available for the thousands of patients currently suffering from this condition who wish to lead a more routine life with fewer incidences of severe diarrhea.”
Carcinoid syndrome is a rare condition that occurs in patients living with mNETsiv and is characterized by frequent and debilitating diarrhea that often prevents patients from leading active, predictable lives, as well as by facial flushing, abdominal pain, fatigue and, over time, heart valve damage.
“The approval of XERMELO establishes a new treatment option for patients with carcinoid syndrome diarrhea that is inadequately controlled by SSA therapy,” said Matthew H. Kulke, M.D., TELESTAR primary investigator, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana Farber Cancer Institute and Professor of Medicine, Harvard Medical School. “Inhibition of tumoral serotonin production represents a novel approach for patients with this condition. Studies have shown that XERMELO can reduce the debilitating effects of carcinoid syndrome diarrhea and has a favorable efficacy and safety profile in patients who currently have limited treatment options.”

About XERMELO
Discovered using Lexicon’s unique approach to gene science, XERMELO is the first and only approved oral therapy for carcinoid syndrome diarrhea. XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within mNET cells.
Lexicon has built the in-house capability and infrastructure to launch and market XERMELO in the U.S., where it retains all commercialization rights. Lexicon also retains rights to market telotristat ethyl in Japan. Lexicon has established a license and collaboration agreement with Ipsen to commercialize telotristat ethyl in Europe and other countries outside of U.S. and Japan. For more information about XERMELO, please visit www.xermelo.com.

XERMELO Important Safety Information
Warnings and Precautions: XERMELO may cause constipation which can be serious. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe persistent or worsening abdominal pain develops.
Adverse Reactions: The most common adverse reactions (≥5%) include nausea, headache, increased GGT, depression, peripheral edema, flatulence, decreased appetite, and pyrexia.
Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 substrates, as XERMELO may decrease their systemic exposure.

For more information about XERMELO, see Full Prescribing Information at www.xermelo.com.

About Lexicon
Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through its Genome5000 program, Lexicon scientists have studied the role and function of nearly 5,000 genes over the last 20 years and have identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism and neuropathic pain. For additional information please visit www.lexpharma.com.

In an effort to ensure all appropriate patients have fast access to affordable treatment, Lexicon offers LexCares—a comprehensive program designed to guide patients through each step of their treatment journey. Through LexCares, patients will have access to financial assistance programs that may reduce or eliminate out-of-pocket costs associated with their XERMELO prescription. For additional information about the LexCares program, visit www.xermelo.com/lexcares.

Safe Harbor Statement
This press release contains “forward‑looking statements,” including statements relating to the safety and efficacy and the therapeutic and commercial potential of XERMELO (telotristat ethyl) 250 mg. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward‑looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the degree of market acceptance of XERMELO, the availability of coverage and reimbursement for XERMELO, Lexicon’s dependence on third parties for manufacturing and distribution of XERMELO, Lexicon’s compliance with applicable legal and regulatory requirements and other factors relating to the commercialization of XERMELO. Other risks include Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other potential drug candidates, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward‑looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10‑K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward‑looking statements, whether as a result of new information, future events or otherwise.
# # #
To read the full press release from Lexicon: xermelo-fda-approval-release-final

Please Follow & Like Us:
Read more

NCAN on Happy Sunday Morning LIVE!

Maryann and Bob Wahmann of NCAN made a live appearance on WLINY Studios LIVE show Happy Sunday Morning with David Gussin to discuss Neuroendocrine Cancer, NCAN, and many upcoming projects and events coming in the NET community!
They also discussed the REAL reason behind choosing the zebra to represent Neuroendocrine Cancers!

You can view their segment on Happy Sunday Morning with David Gussin HERE!  (NCAN segment beginning 24:35 minute mark!)

NCAN would like to send a BIG Thank You to David Gussin and WLINY Studios LIVE for helping spread awareness of Neuroendocrine Cancers and helping NCAN spread the word of our mission!

Please Follow & Like Us:
Read more

BREAKING NEWS! NCAN Introduces NCAN NETCARE

The Neuroendocrine Cancer Awareness Network (NCAN) is excited to announce their new branch, NCAN NETCARE.
NCAN NETCARE is the newest addition to the NCAN family in the continuing efforts to meet the needs of the Neuroendocrine Community. NCAN NETCARE will host accredited CME and CMU programs to reach and continue education of Neuroendocrine Cancers to physicians and nurses.
After years of working towards this expansion, NCAN and NCAN NETCARE are happy to announce their first CME program coming this June in joint production with Stony Brook University, School of Medicine, Office of Continuing Medical Education (OCME) the Accredited Provider, to present Neuroendocrine Tumor Management: Evolving Therapies & Approaches on June 10th, 2017 being held at the Melville Marriott, 1350 Walt Whitman Road, Melville, NY 11747. Neuroendocrine Tumor Management: Evolving Therapies & Approaches will be a CME Catagory 1 credit worth up to 5.00. Registration for Neuroendocrine Tumor Management: Evolving Therapies & Approaches will open April 25th, 2017.
NCAN and their board has expanded on the importance of why they have decided to grow into this space:

“Over the last seven years, there has been dramatic change in the neuroendocrine (NET) field. There have been several large randomized phase III trials of novel treatments completed resulting in new drug approvals. In parallel, there has been an increased understanding of specific biological pathways implicated in neuroendocrine tumor growth. Additionally, significant developments in diagnosis, loco-regional and systemic therapy are rapidly being developed. Consequently, there is a clear need for physicians and allied health care providers to learn about the management options for patients with neuroendocrine tumors, how to sequence treatments and familiarize themselves with new therapeutic, surgical and regional approaches to these diseases.
In light of these rapid developments, we are producing these meetings to draw medical professionals who treat NET patients with the aim of disseminating new information and discussing key clinical trials goals. The intent of the conference is to provide up to date evidence based practice to health care professionals involved in the diagnosis, treatment and management of the patients living with these malignancies. Ultimately this will result in a tremendous benefit to the patient population by improved outcomes and survival.”

More CME and CMU programs will be available throughout the year! Keep an eye out and spread the word to your doctors as these important programs roll out.
NCAN has more exciting and important news to share very soon. Watch for these updates in the coming weeks!

Please Follow & Like Us:
Read more

Announcing! NCAN’s 2018 National NET Patient Conference

NCAN’s 2018 National NET Patient Conference will be in Las Vegas, Nevada, Thursday, September 27th through Saturday, September 29th, 2018. All events will be held at the Green Valley Ranch.
You can check out the Green Valley Ranch here.
Keep your eyes out for all the information to come in the next few months as we prepare to open registration January 2018! We look forward to sharing another great National NET Patient Conference with top doctors giving us the most up-to-date information on NET Cancer!

Please Follow & Like Us:
Read more